drugset
drugset / Trial / NCT02550678

A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma

NCT02550678 ↗

Phase 1/2 Completed 16 enrolled Ascend Biopharmaceuticals Ltd
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study evaluates whether ASN-002 is safe and effective in the treatment of nodular basal cell carcinoma (nBCC) in patients aged 18 years or over. The participants will receive weekly injections of ASN-002 alone or in combination with 5-FU for 3 weeks and undergo surgical excision of the tumor.

Timeline

Start
2015-09
Primary completion
2017-11
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Gusacitinib Small molecule 5e+10 unknown Other
Subject Gusacitinib Small molecule 1.5e+11 unknown Other
Subject Gusacitinib Small molecule 2.25e+11 unknown Other
Subject Gusacitinib Small molecule 3e+11 unknown Other
Subject fluorouracil Small molecule 1 mg Other
Subject fluorouracil Small molecule 2.5 mg Other
Subject fluorouracil Small molecule 5 mg Other
Subject fluorouracil Small molecule 10 mg Other
Subject fluorouracil Small molecule 25 mg Other

Indications

nevoid basal cell carcinoma syndrome nodular basal cell carcinoma